Eesti -
eesti -
Ravimiamet
izgrev õhukese polümeerikattega tablett
swyssi ag - irbesartaan+hüdroklorotiasiid - õhukese polümeerikattega tablett - 12,5mg+150mg 30tk; 150mg+12,5mg 28tk; 12,5mg+150mg 60tk; 150mg+12,5mg 98tk; 12,5mg+150mg 10tk
Eesti -
eesti -
Ravimiamet
izgrev õhukese polümeerikattega tablett
swyssi ag - irbesartaan+hüdroklorotiasiid - õhukese polümeerikattega tablett - 300mg+12,5mg 28tk; 300mg+12,5mg 98tk; 12,5mg+300mg 30tk; 12,5mg+300mg 60tk; 300mg+12,5mg 14tk; 12,5mg+300mg 10tk
Euroopa Liit -
eesti -
EMA (European Medicines Agency)
entresto
novartis europharm limited - sacubitril, valsartan - südamepuudulikkus - angiotensiin ii antagonistidega, muud kombinatsioonid, toimivad ained renin-angiotensiini süsteemi - paediatric heart failureentresto is indicated in children and adolescents aged one year or older for treatment of symptomatic chronic heart failure with left ventricular systolic dysfunction. adult heart failureentresto is indicated in adult patients for treatment of symptomatic chronic heart failure with reduced ejection fraction.
Euroopa Liit -
eesti -
EMA (European Medicines Agency)
neparvis
novartis europharm limited - sacubitril, valsartan - südamepuudulikkus - reniini-angiotensiini süsteemi toimivad ained - paediatric heart failureneparvis is indicated in children and adolescents aged one year or older for treatment of symptomatic chronic heart failure with left ventricular systolic dysfunction (see section 5. adult heart failureneparvis is indicated in adult patients for treatment of symptomatic chronic heart failure with reduced ejection fraction (see section 5.